Ulcerative Colitis Drug Market by Size, Share, Types (Biologics, Corticosteroids, Immunomodulators), Applications (Proctosigmoiditis, Ulcerative proctitis, Pancolitis) and Forecasts by 2027

Global Ulcerative Colitis Drug market was valued at around USD 6.81 billion in 2019 and is expected to grow with the CAGR of 4.35% during forecast period 2021-2027. 

Market Overview:

Ulcerative colitis is an inflammatory bowel disease (IBD) of the large intestine. In this condition, the lining of the colon becomes inflamed and develops tiny open sores or ulcers that causes ulcers (sores) and long-lasting inflammation in the digestive tract. Ulcerative colitis can occur at any age in the lifeline, but it usually starts between the ages of 15 and 30. It tends to run in families. Some of the symptoms of ulcerative colitis are abdominal pain, diarrhoea with mucus, fatigue or tiredness, weight loss, loss of appetite, anaemia, elevated temperature, dehydration, and a constant urge to pass feces. Ulcerative colitis found worldwide but is most common in the United States, northern Europe, and England.

At present, there is no cure for ulcerative colitis, but some medications are available for the treatment of this disease. Several categories of drugs are available in the market in treating ulcerative colitis. The main focus of these drugs is to minimize & control the signs and symptoms of the disease. The treatment and medicines depend on the severity of the condition of the patient and location of ulcerative colitis. Drugs such as corticosteroids, immunomodulator drugs, biologics, and other medications are used to treat the ulcerative colitis effectively. Where medications failed to cure the ulcerative colitis, surgical method is often preferred to eliminate ulcerative colitis. However, it includes the removal of the entire colon and rectum (proctocolectomy); thus, many people avoid surgery and prefer the drugs to treat the ulcerative colitis. The most common ones are mercaptopurine (Purinethol, Purixan), azathioprine (Azasan, Imuran), and cyclosporine (Gengraf, Neoral, and Sandimmune). For many years, immunomodulators were not approved by the FDA to treat people with ulcerative colitis. However, this class of drugs was sometimes used off-label to treat people with ulcerative colitis. In 2018, the FDA approved the use of an immunomodulator for people with ulcerative colitis. 

Market Dynamics:

Drivers:

• The emergence of biosimilars driving the growth of market 

The introduction of biosimilars has revolutionized the management of ulcerative colitis (UC). It is biological therapy used to treat inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease. These drugs are less costly than other drugs, which makes it more accessible in developing countries. In addition to this, many companies are focusing on the development of biosimilars for the treatment of ulcerative colitis, boosting the growth of the market. 

• Growing prevalence of ulcerative colitis

The increasing global incidence of ulcerative colitis, driving the demand for drugs for the cure and treatment. During the study period of more than four decades (1963–2010), prevalence rates increased from 44 to 474 per 100,000, and annual incidence rates of ulcerative colitis increased from 4 to 18 per 100,000. In addition to this, the 2018 Impact of Inflammatory Bowel Disease in Canada report shows that Canada has among the highest prevalence of ulcerative colitis in the world. Thus, increasing incidences and prevalence of ulcerative colitis, demand for drugs has been increased across the globe. 

Restraints:

• Side effects of ulcerative colitis drugs may impact the health 

Adverse effects of a drug used for the treatment of ulcerative colitis may affect the health of person, anticipated to hinder the market growth over the forecast period. Common side effects include rounding of the diabetes, face (moon face), acne, increased body hair, high blood pressure, cataracts, weight gain, and increased susceptibility to infections, glaucoma, muscle weakness, depression, irritability, insomnia, and thinning of the bones. The most severe complication from long term drug use is aseptic necrosis of the hip joints. 

Opportunities:

• Opportunity to develop generic drugs for the treatment of ulcerative colitis

Ulcerative colitis’s branded medications, which are used for the procedure, are expensive. Many patients in the developing cannot afford these costly drugs for the treatment, and thus they avoid the treatment due to the high cost of drugs. Therefore, there is a potential opportunity in the market to develop the generic medication for the ulcerative colitis. Currently, many branded drug’s patents are near to expiration, which offers significant opportunities for the generic drug manufactures in the market. 

Challenges:

• Limited awareness about the ulcerative colitis condition 

Ulcerative colitis (UC) is a lifelong disease progressing over time. Lack of public awareness may contribute to late diagnosis, tardy consultation of primary care physicians, and development of potentially preventable complications of the disease. Thus, limited knowledge about ulcerative colitis among the people may hinder the market growth over the forecast period. 

Segmentation Analysis:

The global ulcerative colitis drug market has been segmented based on type, route of administration, application, distribution channel, and regions.

• The type segment is divided into biologics, corticosteroids, immunomodulators, 5-aminosalicylic acid, immunosuppressant, biosimilars, and others. Biologics accounted for the major market share and valued at USD 2.99 billion in 2019. Biologics is the most widely used drugs for the treatment of ulcerative colitis across the globe. Four biologics, in particular, are FDA approved for treating ulcerative colitis including Humira (adalimumab), Simponi (golimumab), Remicade (infliximab), and Entyvio (vedolizumab).
• The route of administration segment is classified into oral and injectable. Oral segment is anticipated to grow at the highest CAGR of 5.4% over the forecast period. The growth is mainly attributed to increasing preference for oral route of administration over the injectables. An oral route of administration can be used alone in patients who prefer not to use enemas or suppositories to treat the ulcerative colitis. 
• The distribution channel segment includes hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share of 46.2% in the year 2019, due to rise in the number of in-patient and out-patients and presence of advanced facilities in hospitals associated with the disease, which results in high demand for medications of the disease from the hospital pharmacy. 
• The application segment is divided into proctosigmoiditis, ulcerative proctitis, pancolitis, left-sided colitis, acute severe ulcerative colitis, and others. Ulcerative proctitis segment accounted for the largest market share and valued at USD 3.89 billion in 2019. The high incidence rate of ulcerative proctitis, resulting in the high demand for ulcerative colitis drug in this segment. 

Regional Segmentation Analysis:

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and the Middle East and Africa. The North America region emerged as the largest market for the ulcerative colitis drug market with a 44.3% share of the market revenue in 2019.

• This is because North America is growing tremendously in terms of the healthcare industry. North America region has become the hub for the technological development and transformation of the industry. Due to the presence of several technological and pharmaceutical players in countries like Canada and the U.S., North America is projected to dominate the global ulcerative colitis drug market.
• The Asia Pacific region is anticipated to project the growth at the highest CAGR of 7.9% over the forecast period in the global ulcerative colitis drug market. Ulcerative colitis is increasing in many parts of Asia with gender distribution and age of diagnosis similar to North America. In addition to this, growing health awareness among the consumers and rising healthcare expenditure in the region, further driving the growth of the market.  

Competitive Analysis:

Developing and developed countries are offering more significant opportunities and significant players are continuously focused on new developments, strategic partnerships, acquisitions and venture capital investments to obtain high growth in the market. 

In August 2019, Salix Pharmaceuticals, a wholly-owned subsidiary of Bausch Health Companies Inc., announced that its affiliate has entered into licensing agreement with Mitsubishi Tanabe Pharma Corporation (MTPC), to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that plays a role in autoimmune diseases, such as Inflammatory Bowel Disease (IBD) and ulcerative colitis.

In October 2019, Janssen Pharmaceutica, a subsidiary of Johnson & Johnson announced that the U.S. Food and Drug Administration’s (FDA) approval of STELARA (ustekinumab) for the treatment of adult patients with moderately to severely active ulcerative colitis.

List of Key Market Players:

• Bausch Health Companies Inc. (Salix Pharmaceutical)
• AbbVie Inc.
• Johnson and Johnson
• Boehringer Ingelheim GmbH
• Novartis AG
• Merck & Co.
• Teva Pharmaceuticals Ltd.
• Takeda Pharmaceuticals
• Shire
• Pfizer Inc.

Key Target Audience

• Healthcare Institutes
• Drug Manufacturers
• Government Authorities and R&D Institutions
• World Health Organization
• Food and Drug Administration
• Consulting And Research Firm

Major factors covered in this report

• Market Dynamics: Market Drivers and Restraints
• Value-Chain: Supply and Demand Analysis
• Cost and Price Structure Analysis
• Competitive Analysis
• Porter’s Five Forces Analysis

What will the report include?

• Highlights of main global R&D activities and new technological developments
• Estimation of the actual market size and revenue forecasts for global market
• Description of the most relevant research and development activities related to Ulcerative Colitis Drug market places
• Production of Ulcerative Colitis Drug, and review of application for Ulcerative Colitis Drug and assessment of emerging applications
• Analyses of the global market trends, with data from 2020, estimates for 2021, and forecast through 2027
• Review of current industry players, including manufacturers of Ulcerative Colitis Drug, technology developments, and future market participants

Some of the key questions addressed in the report were…

• What were the market size in 2014 and the outlook from 2021 to 2027?
• How much growth will the industry market experience between 2017 and 2027?
• What are the important factors, constraints, and opportunities, and how they will affect market?
• What are the key segments of the Ulcerative Colitis Drug market growth and why?
• Who are the main participants and strategies they use to compete in the market?

Our reports are comprised of thorough analysis which includes business scientific analysis, data engineering, behavioural analysis experts and data strategy statistics based in 15 markets around the world. We use data and intelligence to help our clients build long-term relationship with their consumer.

Minds Insights is the foundation for data driven insights in various industry verticals using four key capabilities:

• Qualitative Research
• Quantitative Research
• Strategy Building
• Research Design